Literature DB >> 33570636

UCD with MCD-like inflammatory state: surgical excision is highly effective.

Miao-Yan Zhang1, Ming-Nan Jia1, Jia Chen1, Jun Feng1, Xin-Xin Cao1, Dao-Bin Zhou1, David C Fajgenbaum2, Lu Zhang1, Jian Li1.   

Abstract

Unicentric Castleman disease (UCD) is a rare lymphoproliferative disorder presenting as a single nodal mass with characteristic histopathology. Patients with UCD are typically asymptomatic with normal laboratory markers, whereas patients with multicentric Castleman disease (MCD) demonstrate multicentric lymphadenopathy and cytokine storm-induced systemic inflammatory symptoms. This retrospective analysis of 116 UCD cases identified 19 (16.4%) cases with an MCD-like inflammatory state (UCD-MIS). We compared treatments and outcomes between cases of UCD-MIS and UCD-non-MIS to evaluate the role of surgery and illuminate biological behavior of UCD-MIS. There were differences in the distribution of histopathological subtypes (plasmacytic histopathology was more frequently seen, 52.6% vs 13.4%; P < .001) between the 2 groups. However, both groups demonstrated good responses to surgical treatment, suggesting that UCD-MIS in some patients still shared common biological behavior with UCD in other patients. Sixteen (94.2%) patients with UCD-MIS underwent complete surgical excision alone, and the systemic inflammation resolved completely in all of them. This high response rate suggests surgical treatment as a potential cure for this unique subset of patients. After a median follow-up duration of 64 months (range, 2-239 months), neither lymphadenopathy nor the inflammatory state recurred. However, inflammation may progress in patients with irresectable disease, and treatment options other than surgery should be considered in these patients.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2021        PMID: 33570636      PMCID: PMC7805307          DOI: 10.1182/bloodadvances.2020003607

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  20 in total

1.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

2.  Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease.

Authors:  Lu Zhang; Ai-Lin Zhao; Ming-Hui Duan; Zhi-Yuan Li; Xin-Xin Cao; Jun Feng; Dao-Bin Zhou; Ding-Rong Zhong; David C Fajgenbaum; Jian Li
Journal:  Blood       Date:  2019-02-13       Impact factor: 22.113

3.  Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.

Authors:  Li Yu; Meifeng Tu; Jorge Cortes; Zijun Y Xu-Monette; Roberto N Miranda; Jun Zhang; Robert Z Orlowski; Sattva Neelapu; Prajwal C Boddu; Mary A Akosile; Thomas S Uldrick; Robert Yarchoan; L Jeffrey Medeiros; Yong Li; David C Fajgenbaum; Ken H Young
Journal:  Blood       Date:  2017-01-18       Impact factor: 22.113

4.  Remission of nephrotic syndrome due to AA amyloidosis and initiation of glomerular repair after surgical resection of localized Castleman's disease.

Authors:  Marcora Mandreoli; Silvia Casanova; Nicola Vianelli; Sonia Pasquali; Pietro Zucchelli
Journal:  Nephron       Date:  2002-03       Impact factor: 2.847

5.  Treatment and outcome of Unicentric Castleman Disease: a retrospective analysis of 71 cases.

Authors:  David Boutboul; Jehane Fadlallah; Sylvain Chawki; Claire Fieschi; Marion Malphettes; Antoine Dossier; Laurence Gérard; Pierre Mordant; Véronique Meignin; Eric Oksenhendler; Lionel Galicier
Journal:  Br J Haematol       Date:  2019-04-23       Impact factor: 6.998

Review 6.  Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature.

Authors:  Iris A C de Vries; Marjolein M S van Acht; Thomas B J Demeyere; Marnix L M Lybeert; Jean-Paul de Zoete; Grard A P Nieuwenhuijzen
Journal:  Radiat Oncol       Date:  2010-02-02       Impact factor: 3.481

Review 7.  HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.

Authors:  David C Fajgenbaum; Frits van Rhee; Christopher S Nabel
Journal:  Blood       Date:  2014-03-12       Impact factor: 22.113

Review 8.  Castleman disease: an update on classification and the spectrum of associated lesions.

Authors:  Danielle M P Cronin; Roger A Warnke
Journal:  Adv Anat Pathol       Date:  2009-07       Impact factor: 3.875

9.  International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

Authors:  Frits van Rhee; Peter Voorhees; Angela Dispenzieri; Alexander Fosså; Gordan Srkalovic; Makoto Ide; Nikhil Munshi; Stephen Schey; Matthew Streetly; Sheila K Pierson; Helen L Partridge; Sudipto Mukherjee; Dustin Shilling; Katie Stone; Amy Greenway; Jason Ruth; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Raj Jayanthan; Elaine S Jaffe; Heather Leitch; Naveen Pemmaraju; Amy Chadburn; Megan S Lim; Kojo S Elenitoba-Johnson; Vera Krymskaya; Aaron Goodman; Christian Hoffmann; Pier Luigi Zinzani; Simone Ferrero; Louis Terriou; Yasuharu Sato; David Simpson; Raymond Wong; Jean-Francois Rossi; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Eric Oksenhendler; David C Fajgenbaum
Journal:  Blood       Date:  2018-09-04       Impact factor: 25.476

10.  Recurrent PDGFRB mutations in unicentric Castleman disease.

Authors:  Zhaoming Li; Xuan Lan; Chaoping Li; Yanjie Zhang; Yingjun Wang; Weili Xue; Lisha Lu; Mengyuan Jin; Zhiyuan Zhou; Xinhua Wang; Ling Li; Lei Zhang; Xin Li; Xiaorui Fu; Zhenchang Sun; Jingjing Wu; Xudong Zhang; Hui Yu; Feifei Nan; Yu Chang; Jiaqin Yan; Xiaolong Wu; Guannan Wang; Dandan Zhang; Yuan Zhang; Ken H Young; Mingzhi Zhang
Journal:  Leukemia       Date:  2019-01-03       Impact factor: 11.528

View more
  3 in total

1.  How we manage idiopathic multicentric Castleman disease.

Authors:  Joshua D Brandstadter; David C Fajgenbaum
Journal:  Clin Adv Hematol Oncol       Date:  2022-09

Review 2.  Castleman disease.

Authors:  Antonino Carbone; Margaret Borok; Blossom Damania; Annunziata Gloghini; Mark N Polizzotto; Raj K Jayanthan; David C Fajgenbaum; Mark Bower
Journal:  Nat Rev Dis Primers       Date:  2021-11-25       Impact factor: 65.038

3.  Transcriptome and unique cytokine microenvironment of Castleman disease.

Authors:  Anna Wing; Jason Xu; Wenzhao Meng; Aaron M Rosenfeld; Elizabeth Y Li; Gerald Wertheim; Michele Paessler; Adam Bagg; Dale Frank; Kai Tan; David T Teachey; Megan S Lim; Eline Luning Prak; David C Fajgenbaum; Vinodh Pillai
Journal:  Mod Pathol       Date:  2021-10-22       Impact factor: 8.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.